Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy
Advances in Clinical and Experimental Medicine · 2025
DOI: 10.17219/acem/210993 ↗Kurz gefasst
Editorial in der Zeitschrift Advances in Clinical and Experimental Medicine, 2025. Verfasst von Yuchen Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Oncolytic Virotherapy, Transforming Growth Factor beta, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zitieren
APA
Sun, Y., Hu, S., Yi, M., & Dai, Z. (2025). Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/210993
Vancouver
Sun Y, Hu S, Yi M, Dai Z. Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy. Advances in Clinical and Experimental Medicine. 2025. doi:10.17219/acem/210993
BibTeX
@article{Sun2025,
author = {Sun, Yuchen and Hu, Shengtao and Yi, Ming and Dai, Zhijun},
title = {Immune reprogramming of cold tumors using TGF-β/PD-L1 bispecific antibody and armed oncolytic virus therapy},
journal = {Advances in Clinical and Experimental Medicine},
year = {2025},
doi = {10.17219/acem/210993}
}
EUVIMED